RBPJL

Across TCGA pan-cancer cohorts, RBPJL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RBPJL data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RBPJL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBPJL expression acts as an unfavorable survival marker.

OV, KIRC, and HNSC are the cancer types where RBPJL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
KIRC	OS	Median	All	0.138	0.655	.019	6	view →
HNSC	OS	Median	All	0.497	0.770	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RBPJL–OV (DFS)

Open the OV breakdown →